Cystatin C and Its Role in Patients with Type 1 and Type 2 Diabetes Mellitus. (5th January 2015)

• Record Type: Journal Article
• Authors: Bashier, Alaaeldin M.; Fadlallah, Ayman Aly Seddik; Alhashemi, Nada; Thadani, Puja Murli; Abdelgadir, Elamin; Rashid, Fauzia
• Other Names: Gohda Tomohito Academic Editor.
• Is Part Of: Advances in endocrinology. Volume 2015(2015)
• Publication Date: 2015-01-05
• Subjects: Endocrinology -- Periodicals; Endocrine glands -- Diseases -- Periodicals; Endocrine glands -- Diseases; Endocrinology; Endocrinology; Endocrine Glands; Periodicals; 616.4
• DOI: 10.1155/2015/254042
• Languages: English
• ISSNs: 2356-668X

Abstract

Abstract : Diabetes mellitus is the commonest cause of CKD. It is the leading cause of new patients requiring renal replacement therapy, accounting for 40%, 34%, and 30% of cases in United States, Germany, and Australia, respectively. Recent studies have shown that a low-molecular weight protein, cystatin C, freely filtered by the kidneys is a novel biomarker that may be used for detection of early renal dysfunction in patients with type 1 or type 2 diabetes. Cystatin C has also been shown to detect cardiovascular disease in patients with diabetes and it may also be linked with incident type 2 diabetes in obese patients. We aim to review current evidence based literature on use of cystatin C for early detection of diabetic nephropathy due to type 1 and type 2 diabetes in comparison to conventional methods and explore its association with other comorbidities.